One-Shot gene therapy aims to cure devastating blood disease
NCT ID NCT05951205
Summary
This was a Phase 3 trial designed to see if a single dose of a gene therapy called exa-cel could cure severe sickle cell disease in adolescents and adults. The treatment aimed to permanently modify a patient's own blood stem cells to stop the disease. The study was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.